Abstract
Allogeneic hematopoietic cell transplantation (HCT) can be curative for both myelodysplastic syndromes (MDS) and lymphoid malignancies. Little is known about the efficacy of allogeneic HCT in patients in whom both myeloid and lymphoid disorders are present at the time of HCT. We analyzed the outcomes in 21 patients with MDS and concurrent lymphoid malignancy when undergoing allogeneic HCT. A total of 17 patients had previously received extensive cytotoxic chemotherapy, including autologous HCT in 7, for non-Hodgkin lymphoma (NHL, n=7), Hodgkin lymphoma (HL, n=2), CLL (n=5), NHL plus HL (n=1), multiple myeloma (n=1) or T-cell ALL (n=1), and had presumably developed MDS as a consequence of therapy. Four previously untreated patients had CLL. A total of 19 patients were conditioned with high-dose (n=14) or reduced-intensity regimens (n=5), and were transplanted from HLA-matched or one Ag/allele mismatched related (n=10) or unrelated (n=9) donors; two patients received HLA-haploidentical related transplants, following a modified conditioning regimen. Currently, 2 of 4 previously untreated and 2 of 17 previously treated patients are surviving in remission of both MDS and lymphoid malignancies. However, the high non-relapse mortality among previously treated patients, even with reduced-intensity conditioning regimens, indicates that new transplant strategies need to be developed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Metayer C, Curtis RE, Vose J, Sobocinski KA, Horowitz MM, Bhatia S et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 2003; 101: 2015–2023.
De Roos AJ, Deeg HJ, Scott D . A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers. Cancer Causes Control 2007; 18: 1199–1208.
Rosenbloom B, Schreck R, Koeffler HP . Therapy-related myelodysplastic syndromes (review). Hematology—Oncology Clinics of North America 1992; 6: 707–722.
André M, Mounier N, Leleu X, Sonet A, Brice P, Henry-Amar M et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood 2004; 103: 1222–1228.
Govindarajan R, Jagannath S, Flick JT, Vesole DH, Sawyer J, Barlogie B et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol 1996; 95: 349–353.
Florensa L, Vallespà T, Woessner S, Domingo A, Crespo N, Rozman M et al. Incidence and characteristics of lymphoid malignancies in untreated myelodysplastic syndromes. Leuk Lymphoma 1996; 23: 609–612.
Mossafa H, Fourcade C, Pulic M, Jary L, Cheze S, Szpiro-Tapia S et al. Chronic lymphocytic leukemia associated with myelodysplastic syndrome and/or chronic myeloid leukemia: evidence for independent clonal chromosomal evolution. Leuk Lymphoma 2001; 41: 337–341.
Sylvester LS, Nowell PC, Bonner H, Moreau L, Moore JS . Concurrent diagnosis of chronic lymphocytic leukemia and myelodysplastic syndrome. Leuk Res 1997; 21: 619–621.
Aviv H, Tang D, Das K, Harrison JS, Hameed M, Varma M . Simultaneous appearance of trisomy 8 and trisomy 12 in different cell populations in a patient with untreated B-cell chronic lymphocytic leukemia and myelodysplasia. Leuk Lymphoma 2004; 45: 1279–1283.
Parmar S, de Lima M . Hematopoietic stem cell transplantation for myelodysplastic syndrome (review). Biol Blood Marrow Transplant 2010; 16: S37–S44.
Wrench D, Gribben JG . Stem cell transplantation for non-Hodgkin's lymphoma (review). Hematology—Oncology Clinics of North America 2008; 22: 1051–1079.
Litzow MR, Tarima S, Perez WS, Bolwell BJ, Cairo MS, Camitta BM et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 2010; 115: 1850–1857.
Chang CK, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 2007; 110: 1379–1387.
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes [erratum appears in Blood 1998 Feb 1;91(3):1100]. Blood 1997; 89: 2079–2088.
Deeg HJ, Storer BE, Boeckh M, Martin PJ, McCune JS, Myerson D et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant 2006; 12: 573–584.
Deeg HJ, Storb R, Thomas ED, Flournoy N, Kennedy MS, Banaji M et al. Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 1985; 65: 1325–1334.
Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–735.
Nash RA, Etzioni R, Storb R, Furlong T, Gooley T, Anasetti C et al. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. Blood 1995; 85: 3746–3753.
Przepiorka D, Weisdorf D, Martin P, Klingemann H-G, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.
Lee SJ, Vogelsang G, Flowers MED . Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 215–233.
Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006; 20: 128–135.
Petersdorf EW, Longton GM, Anasetti C, Mickelson EM, McKinney SK, Smith AG et al. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood 1997; 89: 1818–1823.
Sorror ML, Storer BE, Sandmaier BM, Maris M, Shizuru J, Maziarz R et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008; 26: 4912–4920.
Sato N, Nakazato T, Kizaki M, Ikeda Y, Okamoto S . Transformation of myelodysplastic syndrome to acute lymphoblastic leukemia: a case report and review of the literature (review). Int J Hematol 2004; 79: 147–151.
Thanopoulou E, Cashman J, Kakagianne T, Eaves A, Zoumbos N, Eaves C . Engraftment of NOD/SCID-β2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome. Blood 2004; 103: 4285–4293.
White NJ, Nacheva E, Asimakopoulos FA, Bloxham D, Paul B, Green AR . Deletion of chromosome 20q in myelodysplasia can occur in a multipotent precursor of both myeloid cells and B cells. Blood 1994; 83: 2809–2816.
Mitterbauer G, Schwarzmeier J, Mitterbauer M, Jaeger U, Fritsch G, Schwarzinger I . Myelodysplastic syndrome/acute myeloid leukemia supervening previously untreated chronic B-lymphocytic leukemia: demonstration of the concomitant presence of two different malignant clones by immunologic and molecular analysis. Ann Hematol 1997; 74: 193–197.
Rawstron AC, Bennett FL, O’Connor SJ, Kwok M, Fenton JA, Plummer M et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008; 359: 575–583.
Landgren O, Albitar M, Ma W, Abbasi F, Hayes RB, Ghia P et al. B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med 2009; 360: 659–667.
Campregher PV, Srivastava SK, Deeg HJ, Robins HS, Warren EH . Abnormalities of the αβ T-cell receptor repertoire in advance myelodysplastic syndrome. Exp Hematol 2010; 38: 202–212.
Fozza C, Contini S, Galleu A, Simula MP, Virdis P, Bonfigli S et al. Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset. Exp Hematol 2009; 37: 947–955.
Leone G, Pagano L, Ben Yehuda D, Voso MT . Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 2007; 92: 1389–1398.
de Lima M, Giralt S, Thall PF, De Padua SL, Jones RB, Komanduri K et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010; 116: 5420–5431.
Acknowledgements
We thank all patients for consenting to these studies, the physicians and nurses caring for the patients, Franchesca Nguyen for maintaining the database, and Helen Crawford and Bonnie Larson for their help with the manuscript preparation. We are grateful to the National Institutes of Health, Bethesda, MD, for funding the research through grants P01HL036444, P01CA078902, P01CA018029 and K23HL084054. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, nor its subsidiary Institutes and Centers. Ajay K Gopal is a scholar in clinical research of the Leukemia and Lymphoma Society.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Zimmerman, Z., Scott, B., Gopal, A. et al. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy. Bone Marrow Transplant 47, 804–809 (2012). https://doi.org/10.1038/bmt.2011.180
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2011.180
Keywords
This article is cited by
-
Reply to ‘Allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome’
Bone Marrow Transplantation (2015)
-
Allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome
Bone Marrow Transplantation (2015)